

SPINE SAFETY CAUTIONARY NOTICE:

**Information for Healthcare Professionals:
Drug Safety Labeling Changes -
Zonegran (zonisamide) capsules**

According to MedWatch, FDA notified healthcare professionals that the WARNINGS and PRECAUTIONS text for Zonegran (zonisamide) has been updated. The following sentences have been added to the labeling:

WARNINGS

Metabolic Acidosis

- added safety-related language regarding metabolic acidosis

PRECAUTIONS

Kidney Stones

- Although the clinical significance of the sonographic findings may not be certain, the development of nephrolithiasis may be related to metabolic acidosis.

Information for patients

- Patients should contact their physician immediately if they develop fast breathing, fatigue/tiredness loss of appetite, or irregular heart beat or palpitations (possible manifestations of metabolic acidosis).

Read the complete summary of MedWatch safety labeling changes at:

<http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm212116.htm>

The North American Spine Society is committed to quality patient care through promotion of patient safety and prevention of medical errors. NASS monitors a variety of government and other resources for patient safety related notices that may be useful to our members. Information from these notices is also archived on the NASS website at <http://www.spine.org/Pages/PracticePolicy/ClinicalCare/SpineSafetyAlerts/Default.aspx>. This information is provided as a service for information and education only.